Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00959)
Name
Clotrimazole
Synonyms    Click to Show/Hide the Synonyms of This API
clotrimazole; 23593-75-1; Lotrimin; Canesten; Mycelex; Clotrimazol; Mycosporin; Empecid; Mykosporin; Gyne lotrimin; Chlotrimazole; Trimysten; 1-(o-Chlorotrityl)imidazole; Mycelex G; Rimazole; Mycelex 7; Tibatin; Mono-baycuten; Lotrimin AF Cream; Mycelex Troches; Gyne-Lotrimin; Lotrimin AF Solution; Mycelex OTC; Canestine; Pedisafe; Veltrim; Gynix; Lotrimin Af; Trivagizole 3; 1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole; Desamix F; Mycelex-G; BAY b 5097; Fem Care; Gyne-Lotrimin 3; Mycelex-7; Clotrimazolum; Monobaycuten; (Chlorotrityl)imidazole; Canifug; Lotrimax; Lotrimin AF Jock-Itch Cream; Mycelax; Mycofug; BAY 5097; Mycelex-7 Combination Pack; Gyne-Lotrimin Combination Pack; 1-(o-Chloro-alpha,alpha-diphenylbenzyl)imidazole; Gyne-Lotrimin 3 Combination Pack; Bay-B 5097; 1H-Imidazole, 1-[(2-chlorophenyl)diphenylmethyl]-; FB 5097; Lotrimin (TN); Mycelex (TN); 1-(o-Chlorophenyldiphenylmethyl)imidazole; (2-Chlorophenyl)diphenyl-1-imidazolylmethane; 1-[(2-chlorophenyl)-diphenylmethyl]imidazole; Diphenyl(2-chlorophenyl)(1-imidazolyl)methane; Diphenyl-(2-chlorophenyl)-1-imidazolylmethane; 1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole; NSC 257473; 1-[(2-chlorophenyl)(diphenyl)methyl]-1H-imidazole; Mycelex: MycosporinRimazole; Clotrimazole-d5; Bay b 9057; Prestwick_120; UNII-G07GZ97H65; Bis-phenyl-(2-chlorophenyl)(1-imidazoyl)methane; 1-[(2-Chlorophenyl)diphenylmethyl]-1H-imidazole; Methane, bis-phenyl-(2-chlorophenyl)-1-imidazolyl-; Bisphenyl-(2-chlorphenyl)-1-imidazolyl-methan; Lopac-C-6019; NSC257473; CHEMBL104; 1H-Imidazole, 1-((2-chlorophenyl)diphenylmethyl)-; GNF-Pf-3499; MLS000028502; CHEBI:3764; 1-[(2-chlorophenyl)-diphenyl-methyl]imidazole; G07GZ97H65; Imidazole, 1-(o-chloro-alpha,alpha-diphenylbenzyl)-; MFCD00057220; NSC-257473; NCGC00015251-02; Clotrimaderm; Canestene; Clomatin; Cutistad; Esparol; SMR000058306; Stiemazol; Nalbix; FemCare; Lotrimin Lotion; Canesten Cream; CAS-23593-75-1; Gino-Lotremine; Lotrimin Cream; Mycelex Cream; Myclo Solution; Mycelex Solution; Myclo Cream; DSSTox_CID_9871; Myclo-Gyne; Pan-Fungex; Canesten Solution; Lotrimin Solution; Neo-Zol Cream; Bis-phenyl-(2-chlorophenyl)-1-imidazoyl)methane; DSSTox_RID_78827; Mycelex Twin Pack; DSSTox_GSID_29871; CLT; Lotrimin AF Lotion; Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; 1-(o-Chloro-.alpha.,.alpha.-diphenylbenzyl)imidazole; Myclo Spray Solution; clotrimeizol; Jidesheng; Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; DRG-0072; B 5097; CCRIS 6245; 1185076-41-8; Canesten 1-Day Cream Combi-Pak; HSDB 3266; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; SR-01000075771; EINECS 245-764-8; BRN 0622318; chlortrimazole; clortrimazole; Otomax; 1-((o-Chloro-phenyl)diphenylmethyl)imidazole; Gyne-Lotrimin3; Bis-fenil-(2-clorofenil)-1-imidazolil-metano; Clotrimaderm Cream; Clotrimazole,(S); Bis-fenil-(2-clorofenil)-1-imidazolil-metano [Italian]; Bisphenyl-(2-chlorphenyl)-1-imidazolyl-methan [German]; clotrimazole crystalline; Clotrimazole [USAN:USP:INN:BAN:JAN]; Spectrum_001343; CPD000058306; Clotrimazole (Canesten); Prestwick0_000267; Prestwick1_000267; Prestwick2_000267; Prestwick3_000267; Spectrum2_000128; Spectrum3_000359; Spectrum4_000295; Spectrum5_000781; C 6019; NCIMech_000609; cid_2812; SCHEMBL3850; 1-(2-chlorotrityl)imidazole; BIDD:PXR0036; Lopac0_000315; BSPBio_000114; BSPBio_002057; KBioGR_000850; KBioSS_001823; 5-23-04-00291 (Beilstein Handbook Reference); MLS000758243; MLS001423972; BIDD:GT0450; DivK1c_000665; SPECTRUM1500200; BAY b5097; BAYb 5097; SPBio_000176; SPBio_002333; BPBio1_000126; GTPL2330; component of Otomax (Salt/Mix); DTXSID7029871; Gyne-Lotrimin3 Combination Pack; BDBM31774; Clotrimazole (JP17/USP/INN); HMS502B07; KBio1_000665; KBio2_001823; KBio2_004391; KBio2_006959; KBio3_001277; Imidazole, 1-(o-chloro-.alpha.,.alpha.-diphenylbenzyl)-; component of Lotrimax (Salt/Mix); NINDS_000665; HMS1568F16; HMS1920O21; HMS2051E11; HMS2091G10; HMS2095F16; HMS2235E20; HMS3260P12; HMS3369I03; HMS3393E11; HMS3655I09; HMS3712F16; Pharmakon1600-01500200; Imidazole,.alpha.-diphenylbenzyl)-; BAY-5097; BCP02150; ZINC3807804; Tox21_110111; Tox21_300415; Tox21_500315; CCG-35563; NSC756700; s1606; STK700023; AKOS005607024; Tox21_110111_1; CS-1926; DB00257; LP00315; MCULE-6862012558; NC00035; NSC-756700; SB17418; SDCCGSBI-0050303.P005; IDI1_000665; MRF-0000070; QTL1_000024; NCGC00015251-01; NCGC00015251-03; NCGC00015251-04; NCGC00015251-05; NCGC00015251-06; NCGC00015251-07; NCGC00015251-08; NCGC00015251-09; NCGC00015251-10; NCGC00015251-11; NCGC00015251-13; NCGC00015251-14; NCGC00015251-27; NCGC00093761-01; NCGC00093761-02; NCGC00093761-03; NCGC00093761-04; NCGC00093761-05; NCGC00093761-06; NCGC00254538-01; NCGC00261000-01; [(2-chlorophenyl)diphenylmethyl]imidazole; 1-(o-chloro-a,a-diphenylbenzyl)imidazole; AS-13816; HY-10882; N713; 1-(2-Chloro-?,?-diphenylbenzyl)imidazole; SBI-0050303.P004; AB0015989; Clotrimazole 100 microg/mL in Acetonitrile; DB-046195; 1-[(2-Chlorophenyl)diphenylmethyl]imidazole; 455-EP2272972A1; 455-EP2272973A1; 455-EP2275420A1; 455-EP2277872A1; 455-EP2281816A1; 455-EP2292595A1; 455-EP2295055A2; 455-EP2295416A2; 455-EP2298748A2; 455-EP2298764A1; 455-EP2298765A1; 455-EP2305642A2; 455-EP2311453A1; 455-EP2311808A1; 455-EP2311829A1; AB00051951; EU-0100315; FT-0603193; ST50994242; SW196431-5; C06922; D00282; J10369; 1-(.alpha.-(2-Chlorophenyl)benzhydryl)imidazole; 1-[(2-chlorophenyl)-di(phenyl)methyl]imidazole; AB00051951-14; AB00051951_15; AB00051951_16; Clotrimazole, VETRANAL(TM), analytical standard; 593C751; A816789; Q413546; 1H-Imidazole, 1-[(2-chlorophenyl)-diphenylmethyl]; SR-01000075771-1; SR-01000075771-6; SR-01000075771-8; W-107394; 1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole; BRD-K15916496-001-14-7; SR-01000075771-10; 1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole (9CI); 3ACDFDF8-38E3-4368-85D0-BDF8AE1E6591; Clotrimazole, British Pharmacopoeia (BP) Reference Standard; Clotrimazole, European Pharmacopoeia (EP) Reference Standard; Clotrimazole, United States Pharmacopeia (USP) Reference Standard; Clotrimazole for peak identification, European Pharmacopoeia (EP) Reference Standard; Clotrimazole, Pharmaceutical Secondary Standard; Certified Reference Material; 117829-71-7
Clinical Status
Approved
PubChem CID
2812
Formula
C22H17ClN2
Canonical SMILES
C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4
InChI
1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
InChIKey
VNFPBHJOKIVQEB-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2812"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 344.8 Topological Polar Surface Area 17.8
XlogP 5 Complexity 396
Heavy Atom Count 25 Rotatable Bond Count 4
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 1
Full List of Drug Formulations (DFMs) Containing This API
          Clotrimazole eq 0.05% base cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Benzyl Alcohol; Ceteareth-30; Cetyl Alcohol; Stearyl Alcohol; Mineral Oil; Phosphoric Acid; Propylene Glycol; Purified Water; Sodium Phosphate Monobasic Monohydrate; White Petrolatum
                   Dosage Form Cream
                   Company Merck Sharp Dohme
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Benzyl alcohol DIG Info Indoleamine 2,3-dioxygenase 1 (IC50 = 1400 nM) [1]
Phosphoric acid DIG Info Carbonic anhydrase IV (Ki = 9800 nM) [2]
Cetyl alcohol DIG Info Breast cancer FM3A cells (EC50 = 1600 nM) [3]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
References
1 O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. Eur J Med Chem. 2016 Jan 27; 108:564-576.
2 Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet. Bioorg Med Chem Lett. 2004 Dec 6; 14(23):5763-7.
3 Synthesis and notable antimalarial activity of acyclic peroxides, L-(alkyldioxy)-L-(methyldioxy)cyclododecanes. J Med Chem. 2002 Mar 14; 45(6):1374-8.
4 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.